02/20
Headlines

Gilead Sciences

Hot Biotech Stocks: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD)

Jayne Crisman02 mins

Investment analysts at JPMorgan Chase & Co. dropped their target price on shares of VIVUS (NASDAQ:VVUS) from $8.00 to $5.00 in a note issued to investors on Tuesday, Stock Ratings Network reports. JPMorgan Chase & Co.’s price target would indicate a potential downside of 10.15% from the company’s current price. VIVUS, Inc. (NASDAQ:VVUS)stock performance was…

Read More
Gilead Sciences GILD NASDAQ:GILD

Active Stocks: Endocyte (NASDAQ:ECYT), Gilead Sciences, Inc. (NASDAQ:GILD), Arena Pharmaceuticals (NASDAQ:ARNA), Immunomedics (NASDAQ:IMMU)

Adam Keintzel02 mins

Endocyte (NASDAQ:ECYT)’s shares saw strong trading volume on Friday after the company announced better than expected quarterly earnings, American Banking and Market News reports. 13,778,961 shares changed hands during trading, an increase of 624% from the previous session’s volume of 1,903,723 shares. Endocyte, Inc. (NASDAQ:ECYT) stock performance was 61.91% in last session and finished the…

Read More

Recent Insider Selling: JPMorgan Chase (NYSE:JPM), Micron Technology (NASDAQ:MU), Gilead Sciences (NASDAQ:GILD), Arena Pharmaceuticals (NASDAQ:ARNA)

John Meady02 mins

JPMorgan Chase & Co. (NYSE:JPM) EVP Gordon Smith sold 71,952 shares of the stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $54.91, for a total value of $3,950,884.32. Following the transaction, the executive vice president now directly owns 143,905 shares of the company’s stock,…

Read More
FB Nasdaq FB Facebook

Healthcare Most Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Johnson & Johnson (NYSE:JNJ)

Kristen Barton03 mins

A proxy advisory firm has asked shareholders of the Indian unit of Wyeth to oppose its merger deal with Pfizer Inc. (NYSE:PFE) as the share swap ratio is skewed in favour of Pfizer Inc. (NYSE:PFE). Shareholder Empowerment Services (SES) has made this suggestion ahead of the shareholder meeting this week. Pfizer Inc. (NYSE:PFE) stock performance…

Read More

Healthcare Active Runners: Gilead Sciences (NASDAQ:GILD), Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), MannKind Corporation (NASDAQ:MNKD)

Colin Pettis12 mins

Gilead Sciences, Inc. (NASDAQ:GILD) announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi(R) (sofosbuvir) 400 mg was administered for the treatment of chronic hepatitis C virus (HCV) infection in patients with advanced liver disease. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was -7.32% in last session…

Read More

Investor’s Alert: Gilead Sciences (NASDAQ:GILD), Groupon Inc (NASDAQ:GRPN), Comcast Corporation (NASDAQ:CMCSA), Yahoo! Inc. (NASDAQ:YHOO)

Mark Doerr02 mins

The Egyptian government recently struck a deal with U.S. pharmaceutical firm Gilead Sciences Inc. (NASDAQ:GILD) to purchase its new hepatitis C pill Sovaldi at a fraction of its American price. Under the agreement, Gilead Sciences Inc. (NASDAQ:GILD) will supply a 12-week regimen of Sovaldi to Egypt for 900 dollars, instead of the 84,000 dollars the…

Read More